Form 4: Arcutis Director Sells 10,000 Shares Under 10b5-1 Plan

Arcutis Biotherapeutics Director Howard G. Welgus sold 10,000 shares of common stock for approximately $25.27 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Howard G. Welgus, a Director of Arcutis Biotherapeutics, Inc. (ARQT), sold 10,000 shares of common stock.
• The transaction occurred on November 3, 2025.
• The shares were sold at a weighted average price of $25.2669 per share, with individual transactions ranging from $25.10 to $25.4298.
• Following this transaction, Mr. Welgus beneficially owns 89,744 shares of Arcutis Biotherapeutics common stock.
• This sale was executed pursuant to a Rule 10b5-1 trading plan adopted on March 11, 2025, which has a plan end date of May 29, 2026.

Sentiment

Score: 5

Explanation: While an insider sale can be seen as slightly negative, the fact that it was executed under a pre-arranged 10b5-1 plan adopted well in advance (March 2025 for a November 2025 transaction) significantly mitigates any negative sentiment, making it a largely neutral event.

Positives

• The sale was conducted under a pre-arranged 10b5-1 trading plan, indicating it was not based on new, non-public information and is a routine liquidity event.

Negatives

• A director selling shares, even under a 10b5-1 plan, can sometimes be perceived as a slight negative signal regarding insider confidence, although the pre-planned nature mitigates this concern.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which primarily reports an insider transaction.

Industry Context

Insider transactions, particularly sales by directors, are routinely monitored by investors in the biotechnology and pharmaceutical sectors as they can sometimes offer insights into management's perspective on future company performance. However, sales under pre-arranged 10b5-1 plans are generally viewed as less indicative of a change in sentiment compared to open market sales.

Stakeholder Impact

• Shareholders: The sale by a director, even under a 10b5-1 plan, might be viewed with slight caution by some investors, though the pre-planned nature reduces concerns about opportunistic selling.

Next Steps

• The 10b5-1 trading plan is scheduled to continue until May 29, 2026, implying potential future transactions under the plan.

Key Dates

Recommendation

The transaction is a routine insider sale under a pre-arranged 10b5-1 plan, which does not typically signal a change in the company's fundamental outlook or warrant a change in investment recommendation. It's a planned liquidity event for the director.

Keywords

Arcutis Biotherapeutics, ARQT, insider trading, Form 4, director sale, 10b5-1 plan, equity transaction, common stock